# Comparative Effectiveness of Empagliflozin in the US

> **NCT03363464** · — · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 230000 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** DPP-4 inhibitor
- **DRUG:** GLP-1 receptor agonist

## Key facts

- **NCT ID:** NCT03363464
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-16
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 230000 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363464, "Comparative Effectiveness of Empagliflozin in the US". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03363464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*